Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Should You Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $16.00, but opened at $15.40. Ascentage Pharma Group International shares last traded at $15.5150, with a volume of 1,471 shares traded.

Analyst Ratings Changes

AAPG has been the topic of several research analyst reports. B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target on the stock. BTIG Research reissued a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Finally, Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. Based on data from MarketBeat, Ascentage Pharma Group International currently has a consensus rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Stock Down 1.6%

The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18. The company’s fifty day moving average price is $17.87 and its 200 day moving average price is $20.20.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million during the quarter. Equities analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.

The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins.